# A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

> **NCT05083923** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 136 (actual)

## Conditions studied

- Relapsing Forms of Multiple Sclerosis

## Interventions

- **DRUG:** Diroximel fumarate

## Key facts

- **NCT ID:** NCT05083923
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-18
- **Primary completion:** 2024-09-11
- **Final completion:** 2024-09-11
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05083923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05083923, "A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05083923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*